Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash & Current Investments (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Cash & Current Investments data on record, last reported at $248.5 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 1.48% year-over-year to $248.5 million; the TTM value through Dec 2025 reached $248.5 million, up 1.48%, while the annual FY2025 figure was $248.5 million, 1.48% up from the prior year.
  • Cash & Current Investments reached $248.5 million in Q4 2025 per CCCC's latest filing, up from $191.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $465.9 million in Q2 2021 and bottomed at $191.9 million in Q3 2025.
  • Average Cash & Current Investments over 5 years is $279.0 million, with a median of $265.7 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 332.79% in 2021, then crashed 33.94% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $309.3 million in 2021, then dropped by 10.71% to $276.2 million in 2022, then fell by 8.14% to $253.7 million in 2023, then fell by 3.46% to $244.9 million in 2024, then rose by 1.48% to $248.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $248.5 million in Q4 2025, $191.9 million in Q3 2025, and $214.6 million in Q2 2025.